BlackRock Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

BlackRock Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$225K	Sell	10,855 -493	-4%	-$8.26K	﹤0.01%	2670
2016 Q3	$184K	Buy	11,348 +1,546	+16%	+$22.4K	﹤0.01%	2732
2016 Q2	$133K	Buy	9,802 +1,338	+16%	+$23.7K	﹤0.01%	2818
2016 Q1	$148K	Buy	8,464 +615	+8%	+$12.5K	﹤0.01%	2712
2015 Q4	$268K	Sell	7,849 -2,103	-21%	-$72.9K	﹤0.01%	2401
2015 Q3	$296K	Buy	9,952 +154	+2%	+$4.68K	﹤0.01%	2508
2015 Q2	$313K	Buy	9,798 +4,325	+79%	+$111K	﹤0.01%	2513
2015 Q1	$113K	Buy	5,473 +561	+11%	+$9.69K	﹤0.01%	2981
2014 Q4	$83K	Hold	4,912	–	–	﹤0.01%	3132
2014 Q3	$95K	Sell	4,912 -53,670	-92%	-$1.4M	﹤0.01%	3032
2014 Q2	$1.99M	Buy	58,582 +8,916	+18%	+$279K	﹤0.01%	1180
2014 Q1	$1.56M	Buy	+49,666	New	+$1.55M	﹤0.01%	1280

Other funds holding RVNC

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

BlackRock Advisors's RVNC Position: Q4 2016 in Review

BlackRock Advisors reduced its Revance Therapeutics, Inc. (RVNC) stake by 4.3% in Q4 2016, selling an estimated $8.26K and leaving 10,855 shares worth $225K. The position accounts for ﹤0.01% of the portfolio, ranked #2670.

BlackRock Advisors first reported a position in RVNC in Q1 2014 and has held it in 12 quarters since. The position peaked at $1.99M in Q2 2014. 81 funds tracked by Wall St. Rank hold RVNC as of Q4 2016.

BlackRock Advisors held 10,855 shares of Revance Therapeutics, Inc. worth $225K as of Q4 2016.
BlackRock Advisors sold 493 Revance Therapeutics, Inc. shares in Q4 2016, an estimated $8.26K.
Revance Therapeutics, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2670 holding.
BlackRock Advisors first reported a position in Revance Therapeutics, Inc. in Q1 2014 and has held it in 12 quarters since.
BlackRock Advisors's Revance Therapeutics, Inc. position peaked at $1.99M in Q2 2014.
81 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.